SCHEMBL1572822

SCHEMBL1572822

Cc1c(NC(=O)c2cccc(OCCNC(=O)CCC(=O)NCCOc3cccc(C(=O)Nc4c(C)c(C(=O)c5ccc(N)c(C(=O)O)c5)n5ccccc45)c3)c2)c2ccccn2c1C(=O)c1ccc(N)c(C(=O)O)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 2/20 0.38
ALDH1A1 P00352 6/20 0.36
AKR1C2 P52895 1/20 0.36
AKR1C1 Q04828 1/20 0.36
HDAC3 O15379 2/20 0.36
NR1H4 Q96RI1 3/20 0.35
POLB P06746 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
HPGD P15428 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13918726 0.96 F10 (0.38) F10ALDH1A1AKR1C2AKR1C1HDAC3
SCHEMBL1573017 0.94 F10 (0.39) F10ALDH1A1AKR1C2AKR1C1HDAC3
SCHEMBL1573409 0.91 ALDH1A1 (0.43) ALDH1A1MEN1KMT2AHPGDNPSR1
SCHEMBL1573171 0.91 NR1H4 (0.42) ALDH1A1AKR1C2AKR1C1NR1H4MEN1
SCHEMBL4518702 0.90 MEN1 (0.38) ALDH1A1AKR1C2AKR1C1NR1H4MEN1
SCHEMBL1573416 0.90 ALDH1A1 (0.38) ALDH1A1AKR1C2AKR1C1NR1H4MEN1
SCHEMBL1572784 0.90 ALDH1A1 (0.42) ALDH1A1HDAC3MEN1KMT2AHPGD
SCHEMBL1573140 0.90 ALDH1A1 (0.42) ALDH1A1HDAC3MEN1KMT2AHPGD
SCHEMBL4519842 0.89 ALDH1A1 (0.42) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL4508873 0.88 AKR1C2 (0.40) F10ALDH1A1AKR1C2AKR1C1NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9120819-B2 FGF-receptor agonist dimeric compounds SANOFI (FR) 2015-09-01 US claimed
EP-2018165-B1 FGF-PECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI AVENTIS (FR) 2011-04-13 EP claimed
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI-AVENTIS (FR) 2009-03-12 US claimed
US-9120819-B2 FGF-receptor agonist dimeric compounds SANOFI (FR) 2015-09-01 US disclosed
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI-AVENTIS (FR) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS FGF2, FGFR1, FGF1 F10 607/4885ALDH1A1 1044/4885AKR1C2 1971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.